Redeye is only making minimal changes to our forecasts on the back of the Q3 report.
Redeye updates its estimates ahead of CTEK’s Q3 report, which is due on 14 November.
Redeye updates its estimates and valuation following Vitec releasing its Q3 2024 report.
The recent period of strong revenue growth may have come to an end in Q2, as we expect negative reve...
Q3e: Medical stable, cyclical risk in Engineered Estimates lowered by 2% p.
Q3e: EBIT +9% y-o-y, core bitumen operations stable Rate cuts should support gradual recovery from H...
Rec PTP -3% vs ABGSCe, driven by topline New swap agreements of ~SEK 835m Share to trade slightly be...
Umida Group AB (”Umida”, ”koncernen” eller ”bolaget”) meddelade den 17 oktober år 2024 utfallande av...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 16 oktober år 202...
Redeye sees only minor deviations from our expectations in Powercells’ Q3 report.
Redeye provides its initial take on Vitec’s Q3 2024 report, which came in slightly below our estimat...
Hansa delivers a healthy increase in patients using IDEFIRIX.
Q3e: sales of SEK 50m (up 10%), EBIT of SEK 1.5m (-2.
Redeye comments on InfraCom's reported data breach, affecting over 10.
DT reports Q3 results on Oct 29. The growth rate of MBU still lags those of SBU and IBU, but its sta...
Etteplan issued its second profit warning of the fiscal year prior to the Q3 report, citing ongoing ...
Sales growth of +7.8% and 20% EBIT margin in Q3e EBITDA '24e-'26e revised down 1.
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 15 oktober att Bolaget lanserar en högprest...
Redeye expects a stable Q2 report from Lagercrantz with muted organic growth yet solid margins.
Redeye provides a brief comment on Freemelt's order from a global orthopedic implant OEM, marking a ...
